To review the role of sincalide in treating and preventing parenteral nutrition (PN)–associated gallbladder disease.
DATA SOURCES
A MEDLINE (1996–March 2004) search was performed using the key terms cholecystokinin, sincalide, parenteral nutrition, cholelithiasis, cholestasis, and sludge.
DATA SYNTHESIS
Five human studies investigated the safety and efficacy of sincalide in patients with PN-associated gallbladder disease. Sincalide at intravenous doses of 0.04 μg/kg 3 times daily increased bile flow and improved serum bilirubin levels. However, patients with advanced liver disease did not respond to sincalide therapy. Long-term follow-up data on sincalide effects on liver disease progression are not yet available.
CONCLUSIONS
Sincalide improved the signs of cholestasis. However, its long-term effects in preventing and treating PN-associated gallbladder disease remain unknown and its routine use for this indication cannot be recommended at this time.
. GurllNJ, MeyerPD, DenBestenL. The effect of cholesterol crystals on gallbladder function in cholelithiasis. Surg Forum1977; 28: 412–3.
4.
. AllenB, BernhoftR, BlanckaertN, SvanvikJ, FillyR, GoodingG, Sludge is calcium bilirubinate associated with bile stasis. Am J Surg1981; 141: 51–6.
5.
. CooperA, RossAJ3rd, O'NeillJA, BishopHC, TempletonJMJr, ZieglerMM. Resolution of intractable cholestasis associated with total parenteral nutrition following biliary irrigation. J Pediatr Surg1985; 20: 772–4.
6.
. MessingB, BoriesC, KunstlingerF, BernierJJ. Does total parenteral nutrition induce gallbladder sludge formation and lithiasis?Gastroenterology1983; 84 (5 pt 1): 1012–9.
7.
. RoslynJJ, PittHA, MannLL, AmentME, DenBestenL. Gallbladder disease in patients on long-term parenteral nutrition. Gastroenterology1983; 84: 148–54.
8.
. Ginn-PeaseME, PantalosD, KingDR. TPN-associated hyperbilirubinemia: a common problem in newborn surgical patients. J Pediatr Surg1985; 20: 436–9.
9.
. BellRL, FerryGD, SmithEO, ShulmanRJ, ChristensenBL, LabartheDR, Total parenteral nutrition–related cholestasis in infants. JPEN J Parenter Enteral Nutr1986; 10: 356–9.
10.
. DrongowskiRA, CoranAG. An analysis of factors contributing to the development of total parenteral nutrition–induced cholestasis. JPEN J Parenter Enteral Nutr1989; 13: 586–9.
11.
. PittHA, KingW3rd, MannLL, RoslynJJ, BerquistWE, AmentME, Increased risk of cholelithiasis with prolonged total parenteral nutrition. Am J Surg1983; 145: 106–12.
12.
. RoslynJJ, BerquistWE, PittHA, MannLL, KangarlooH, DenBestenL, Increased risk of gallstones in children receiving total parenteral nutrition. Pediatrics1983; 71: 784–9.
13.
. CanianoDA, StarrJ, Ginn-PeaseME. Extensive short-bowel syndrome in neonate: outcome in the 1980s. Surgery1989; 105: 119–24.
14.
. PalmerRH, HrubanZ. Production of bile duct hyperplasia and gallstones by lithocholic acid. J Clin Invest1966; 45: 1255–66.
. BeathSV, NeedhamSJ, KellyDA, BoothIW, RaafatF, BuickRG, Clinical features and prognosis of children assessed for isolated small bowel or combined small bowel and liver transplantation. J Pediatr Surg1997; 32: 459–61.
17.
. LiddleRA, GoldfineID, RosenMS, TaplitzRA, WilliamsJA. Cholecystokinin bioactivity in human plasma. Molecular forms, responses to feeding, and relationship to gallbladder contraction. J Clin Invest1985; 75: 1144–52.
18.
. MashakoMN, BernardC, CezardJP, ChayvialleJA, NavarroJ. Effect of total parenteral nutrition, constant rate enteral nutrition, and discontinuous oral feeding on plasma cholecystokinin immunoreactivity in children. J Pediatr Gastroenterol Nutr1987; 6: 948–52.
19.
. O'KeefeSJ, LeeRB, AndersonFP, GenningsC, Abou-AssiS, CloreJ, Physiological effects of enteral and parenteral feeding on pancreaticobiliary secretion in humans. Am J Physiol Gastrointest Liver Physiol2003; 284: G27–36.
20.
. KalfarentzosF, SpiliotisJ, ChalmoukisA, VagenasC, VagenakisA. Gallbladder contraction after hormonal manipulations in normal subjects and patients under total parenteral nutrition. J Am Coll Nutr1992; 11: 17–20.
. LevantJA, KunTL, JachnaJ, SturdevantRA, IsenbergJI. The effects of graded doses of C-terminal octapeptide of cholecystokinin on small intestinal transit time in man. Am J Dig Dis1974; 19: 207–9.
. DotyJE, PittHA, Porter-FinkV, DenBestenL. Cholecystokinin prophylaxis of parenteral nutrition–induced gallbladder disease. Ann Surg1985; 201: 76–80.
25.
. InnisSM. Effect of cholecystokinin–octapeptide on total parenteral nutrition–induced changes in hepatic bile secretion and composition in the rat. J Pediatr Gastroenterol Nutr1986; 5: 793–8.
26.
. CurranTJ, UzoaruI, DasJB, AnsariG, RaffenspergerJG. The effect of cholecystokinin–octapeptide on the hepatobiliary dysfunction caused by total parenteral nutrition. J Pediatr Surg1995; 30: 242–7.
27.
. DawesLG, MuldoonJP, GreinerMA, BertolottiM. Cholecystokinin increases bile acid synthesis with total parenteral nutrition but does not prevent stone formation. J Surg Res1997; 67: 84–9.
. RintalaRJ, LindahlH, PohjavuoriM. Total parenteral nutrition–associated cholestasis in surgical neonates may be reversed by intravenous cholecystokinin: a preliminary report. J Pediatr Surg1995; 30: 827–30.
30.
. TeitelbaumDH, Han-MarkeyT, SchumacherRE. Treatment of parenteral nutrition associated cholestasis with cholecystokinin–octapeptide. J Pediatr Surg1995; 30: 1082–5.
31.
. TeitelbaumDH, Han-MarkeyT, DrongowskiRA, CoranAG, BayarB, GeigerJD, Use of cholecystokinin to prevent the development of parenteral nutrition–associated cholestasis. JPEN J Parenter Enteral Nutr1997; 21: 100–3.
